In part 4 of this Exclusive Interview, Andrea Dunaif talks with Diabetes in Control Medical Editor Joy Pape about the ease of diagnosing PCOS.Read More »
In part 5 of this Exclusive Interview, Andrea Dunaif talks with Diabetes in Control Medical Editor Joy Pape about the complexities behind the misnomer PCOS.Read More »
In part 6, the conclusion of this Exclusive Interview, Andrea Dunaif talks with Diabetes in Control Medical Editor Joy Pape about the steps to take if PCOS is suspected.Read More »
Specific treatment recommendations outlined for this growing patient population.Read More »
Study assesses the prevalence of complications following regular use of cannabis.Read More »
The Delayed Effect of Dietary Change on Insulin Sensitivity in Children with a Family History of Obesity
Variations in certain macronutrients may be correlated to change in insulin sensitivity/resistance.Read More »
GLP-1 treatment benefits patients on statins and with varying LDL levels.Read More »
Stricter Treatment Targets for Gestational Diabetes Leads to Earlier Births, No Difference in Birth Weight
New study shows implementing tighter treatment goals for GDM does not improve birth weight in neonates, but may increase risk for earlier birth and clinician intervention.Read More »
Study focuses on score accuracy to improve prediction models for the better.Read More »
John S. is a 63-year-old white man with significant abdominal obesity, type 2 diabetes, hypertension, and dyslipidemia as well. On the basis of an exercise stress test, John was recently diagnosed with silent ischemia. John’s current medications include metformin, a DPP-4 inhibitor, an ACE inhibitor/HCTZ agent, a calcium channel blocker, a high-dose statin, and ezetimibe. John’s relevant physical exam and laboratory findings are as follows:
BMI: 34.8 kg/m2
Blood pressure: 140/86 mm Hg
Total cholesterol: 150 mg/dL
LDL-C: 79 mg/dL
HDL-C: 42 mg/dL
Triglycerides: 145 mg/dL
non-HDL-C: 118 mg/dL
eGFR: 65 mL/min/1.73 m2
ACR: 100 mg albumin/g creatinine
Which statement best describes the evidence supporting cardiovascular benefits of the antihyperglycemic agents available to treat John’s type 2 diabetes?
A. Further glucose reduction using any available agent should have similar cardiovascular disease benefit.
B. Thiazolidinediones increase the risk of heart failure and myocardial infarction in patients with type 2 diabetes.
C. Two approved GLP-1 receptor agonists have been shown to reduce mortality in patients with type 2 diabetes and cardiovascular disease.
D. Both GLP-1 receptor agonists and SGLT2 inhibitors affect cardiovascular risk through the same physiologic mechanisms.
Follow the link for the answer.Read More »